8-K: Applied Therapeutics Announces Positive Interim Results for SORD Deficiency Trial and Provides Corporate Update

Applied Therapeutics released a corporate presentation and positive interim 12-month results from its Phase 3 INSPIRE trial for SORD Deficiency, showcasing the potential of its lead drug candidate, govorestat.

Summary

• Applied Therapeutics has released a corporate overview and interim results from the Phase 3 INSPIRE trial for SORD Deficiency.
• The INSPIRE trial is evaluating AT-007 (govorestat) in patients with SORD Deficiency.
• The 12-month interim data showed a statistically significant correlation between reduced sorbitol levels and improved clinical outcomes.
• Govorestat demonstrated a statistically significant reduction in sorbitol levels compared to placebo (p<0.001).
• The study also showed a statistically significant improvement in the CMT Health Index (CMT-HI) for patients treated with govorestat (p=0.01).
• The company's pipeline includes treatments for Galactosemia, Diabetic Cardiomyopathy, and PMM2-CDG.
• Govorestat has shown effectiveness in reducing galactitol levels in Galactosemia patients and has received regulatory submissions.
• AT-001 for Diabetic Cardiomyopathy showed a positive trend in a Phase 3 study, with statistically significant results in a subgroup of patients not on SGLT2 or GLP1 treatments.
• The company is pursuing expedited regulatory pathways for its treatments.
• Applied Therapeutics is targeting fatal or debilitating diseases with no approved therapies and limited competition.

Sentiment

Score: 8

Explanation: The document presents positive interim results from a key clinical trial and highlights the potential of the company's pipeline. The focus on rare diseases with unmet needs and the pursuit of expedited regulatory pathways are also positive indicators. However, the document also acknowledges risks and uncertainties, which tempers the overall sentiment.

Positives

• The INSPIRE trial for SORD Deficiency showed a statistically significant correlation between reduced sorbitol levels and improved clinical outcomes.
• Govorestat demonstrated a significant reduction in sorbitol levels and improvement in the CMT Health Index.
• The company has a diverse pipeline targeting multiple rare diseases with high unmet needs.
• Govorestat has shown positive results in both Galactosemia and SORD Deficiency trials.
• AT-001 for Diabetic Cardiomyopathy showed a positive trend in a Phase 3 study.
• The company is pursuing expedited regulatory pathways for its treatments.
• The company has strong intellectual property protection for its key programs.
• The company has a focus on fatal or debilitating diseases with no approved therapies and limited competition.

Negatives

• The Phase 3 study for Diabetic Cardiomyopathy did not meet its primary endpoint in the overall population, but did show a statistically significant result in a subgroup.
• Some clinical outcome measures in the SORD Deficiency trial showed trends but were not statistically significant.
• There were some treatment-related discontinuations in the Diabetic Cardiomyopathy trial.

Risks

• The company's forward-looking statements are subject to numerous risks and uncertainties.
• There is a risk of failure to demonstrate the safety, tolerability, and efficacy of product candidates.
• Obtaining regulatory approval from the FDA and EMA is expensive and uncertain.
• The company relies on third parties for its technologies and product candidates.
• There are risks related to the company's intellectual property position and patent rights.
• Biopharmaceutical products are subject to stringent ongoing governmental regulation and competition.
• The company's ability to fund its working capital requirements is a risk.

Future Outlook

The company anticipates continued development of its pipeline, including the completion of the Phase 3 INSPIRE trial for SORD Deficiency and regulatory submissions for Galactosemia. The company also expects to continue the development of AT-001 for Diabetic Cardiomyopathy.

Management Comments

• The company's mission is to create transformative, life-changing treatments for patients who desperately need them.
• The company is targeting pathways with known roles in pathogenesis.
• The company is pursuing expedited regulatory pathways for its treatments.

Industry Context

This announcement highlights the company's progress in developing treatments for rare and metabolic diseases, which are areas of significant unmet medical need. The focus on Aldose Reductase inhibition aligns with a growing interest in targeting metabolic pathways for therapeutic intervention. The company's approach of using biomarkers to confirm clinical efficacy is also a trend in the industry.

Comparison to Industry Standards

• Applied Therapeutics is developing Aldose Reductase Inhibitors (ARIs), a class of drugs that has faced challenges in the past due to lack of selectivity and off-target effects. The company claims its compounds are 1,000X more potent and highly selective compared to older ARIs like zopolrestat.
• For Galactosemia, the company is targeting a rare disease with no approved therapies, similar to other companies focusing on orphan drug development. The company's approach of using galactitol reduction as a biomarker is consistent with industry standards for rare disease drug development.
• In SORD Deficiency, the company is addressing a rare neuropathy with no approved treatments, similar to other companies developing therapies for Charcot-Marie-Tooth disease and other inherited neuropathies. The use of the CMT-HI as a patient-reported outcome measure is a common practice in this field.
• For Diabetic Cardiomyopathy, the company is targeting a large patient population with a significant unmet need. The company's approach of using peak VO2 as a primary endpoint is consistent with industry standards for heart failure trials. The company's results are comparable to other companies developing treatments for heart failure, such as those targeting SGLT2 and GLP1 pathways.

Stakeholder Impact

• Shareholders will likely react positively to the positive clinical trial results and pipeline progress.
• Patients with Galactosemia and SORD Deficiency may benefit from the development of new treatments.
• Employees may be motivated by the company's progress and mission.
• Customers and suppliers may see increased business opportunities with the company.

Next Steps

• The INSPIRE trial will continue in a blinded format to 24 months.
• The company will continue to pursue regulatory submissions for govorestat in Galactosemia.
• The company will continue the development of AT-001 for Diabetic Cardiomyopathy.
• The company will continue to engage with the Galactosemia community through social media and educational resources.

Key Dates

Keywords

SORD Deficiency, Galactosemia, Diabetic Cardiomyopathy, Aldose Reductase Inhibitor, Govorestat, AT-007, AT-001, Clinical Trial, Rare Disease, Neuropathy, Metabolic Disease, Biomarker, Orphan Drug Designation, Pediatric Rare Disease Designation